Pharvaris Presents Deucrictibant Data at CIIC Conference
Pharvaris presented data evaluating safety margins of administration of deucrictibant immediate-release, or IR, capsule in combination with deucrictibant extended-release, or XR, tablet at the Consortium of Independent Immunology Clinics, or CIIC, Spring 2026 Conference, which took place from April 17-19, 2026, in Arlington, TX. A recently published post-hoc analysis of the prophylaxis CHAPTER-1 study assessed the mean duration of breakthrough attacks, in both placebo and deucrictibant arms, that were treated with a single dose of icatibant, another bradykinin B2 receptor antagonist. The comparable mean total duration of icatibant-treated attacks in the placebo-icatibant and the deucrictibant-icatibant groups provide initial evidence on the efficacy of combining use of a bradykinin B2 receptor antagonist for prophylaxis and on-demand treatment of attacks.
Trade with 70% Backtested Accuracy
Analyst Views on PHVS
About PHVS
About the author
Pharvaris CEO Sells 23,333 Shares Amid Strong Stock Performance
- Insider Sale: On April 9, 2026, Pharvaris CEO Berndt Modig sold 23,333 common shares for approximately $647,000, reducing his direct holdings to 142,084 shares, indicating routine liquidity management under his trading plan.
- Stake Analysis: This sale represented 14.11% of Modig's direct stake but only 2.09% of his total holdings, suggesting confidence in the company as he retains over 900,000 shares indirectly.
- Market Price Comparison: The weighted average sale price of $27.74 per share was slightly above the latest closing price of $26.63 on April 10, 2026, indicating a strategic decision to sell at a high point amidst market fluctuations.
- Investor Considerations: Despite Pharvaris not generating revenue and reporting a net loss of €176 million in 2025, its cash reserves increased to €292 million, providing operational funding, while investors should monitor the approval status of its treatment options before making investment decisions.
Pharvaris Reports Q4 Loss of €46.7 Million
- Financial Performance: Pharvaris reported a Q4 loss of €46.7 million, resulting in a basic and diluted loss per share of €0.72, indicating significant pressure from R&D and operational expenditures that may affect future financing capabilities.
- Market Reaction: The ongoing losses may undermine investor confidence in Pharvaris, leading to increased stock price volatility and impacting the company's positioning in the biopharmaceutical sector.
- Conference Presentations: Pharvaris showcased its developments at the 2026 Global Angioedema Leadership Conference and the AAAAI Annual Meeting, aiming to enhance brand visibility and attract potential investors despite its poor financial performance.
- Historical Financial Data: The disclosure of historical financial data reveals a trend of sustained losses over recent quarters, potentially raising market concerns about the company's long-term sustainability.
Pharvaris N.V. (PHVS) Price Target Raised by 20.90% to $45.73
Price Target Update: The average one-year price target for Pharvaris N.V. has been revised to $45.73 per share, reflecting a 20.90% increase from the previous estimate of $37.82, with a range from $30.30 to $80.85 per share.
Fund Sentiment: There has been a 29.21% increase in the number of funds reporting positions in Pharvaris, with total shares owned by institutions rising by 28.49% to 58,210K shares, and an average portfolio weight of 1.67%.
Shareholder Activity: General Atlantic increased its holdings in Pharvaris by 6.23% to 8,031K shares, while Foresite Capital Management Iv and venBio Partners also reported increases in their share ownership, with venBio Partners slightly decreasing its portfolio allocation.
Market Outlook: The put/call ratio for Pharvaris is at 0.93, indicating a bullish sentiment among investors, suggesting positive expectations for the stock's performance.
Stocks Rise on Hope for Fed Rate Cuts
Market Performance: The S&P 500, Dow Jones, and Nasdaq 100 all closed higher on Wednesday, with the S&P 500 and Nasdaq reaching three-week highs, supported by a weaker-than-expected ADP employment report that lowered bond yields and increased expectations for a Fed interest rate cut.
Sector Highlights: Chipmakers saw significant gains, with Microchip Technology rising over 12% after a strong earnings forecast, while other tech stocks also performed well. Conversely, concerns over AI demand affected Microsoft, which saw a decline in stock price.
Economic Indicators: The November ADP employment report indicated an unexpected job loss of 32,000, the largest drop in over 2.5 years, while the ISM services index showed unexpected growth, suggesting mixed signals in the labor market and economic activity.
Upcoming Economic Focus: Market attention is on upcoming economic reports, including unemployment claims and personal spending, with a high probability of a 25 basis point rate cut anticipated at the next FOMC meeting on December 9-10.
Stocks Bounce Back Amid Anticipation of Fed Rate Cuts
Market Performance: The S&P 500 is up 0.18%, while the Dow Jones is up 0.47%, and the Nasdaq 100 is down 0.06%. Stock indexes recovered from early losses due to falling bond yields and expectations of a Fed interest rate cut following a weaker-than-expected ADP employment report.
Labor Market Concerns: The November ADP employment report revealed an unexpected job loss of 32,000, the largest decline in over 2.5 years, raising concerns about the labor market's strength and its implications for economic growth.
Corporate Earnings and Economic Indicators: Q3 earnings for S&P 500 companies have exceeded forecasts, with a 14.6% increase, while the ISM services index unexpectedly rose, indicating stronger service-sector activity. Market attention is on upcoming economic reports, including unemployment claims and personal spending.
Stock Movements: Chipmakers like Microchip Technology and Marvell Technology saw significant gains, while stocks like Pure Storage and Gitlab faced declines due to disappointing forecasts. Additionally, cryptocurrency-related stocks rose as Bitcoin reached a two-week high.
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.
Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.
Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.
Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.
Pharvaris CEO Sells 23,333 Shares Amid Strong Stock Performance
- Insider Sale: On April 9, 2026, Pharvaris CEO Berndt Modig sold 23,333 common shares for approximately $647,000, reducing his direct holdings to 142,084 shares, indicating routine liquidity management under his trading plan.
- Stake Analysis: This sale represented 14.11% of Modig's direct stake but only 2.09% of his total holdings, suggesting confidence in the company as he retains over 900,000 shares indirectly.
- Market Price Comparison: The weighted average sale price of $27.74 per share was slightly above the latest closing price of $26.63 on April 10, 2026, indicating a strategic decision to sell at a high point amidst market fluctuations.
- Investor Considerations: Despite Pharvaris not generating revenue and reporting a net loss of €176 million in 2025, its cash reserves increased to €292 million, providing operational funding, while investors should monitor the approval status of its treatment options before making investment decisions.
Pharvaris Reports Q4 Loss of €46.7 Million
- Financial Performance: Pharvaris reported a Q4 loss of €46.7 million, resulting in a basic and diluted loss per share of €0.72, indicating significant pressure from R&D and operational expenditures that may affect future financing capabilities.
- Market Reaction: The ongoing losses may undermine investor confidence in Pharvaris, leading to increased stock price volatility and impacting the company's positioning in the biopharmaceutical sector.
- Conference Presentations: Pharvaris showcased its developments at the 2026 Global Angioedema Leadership Conference and the AAAAI Annual Meeting, aiming to enhance brand visibility and attract potential investors despite its poor financial performance.
- Historical Financial Data: The disclosure of historical financial data reveals a trend of sustained losses over recent quarters, potentially raising market concerns about the company's long-term sustainability.
Pharvaris N.V. (PHVS) Price Target Raised by 20.90% to $45.73
Price Target Update: The average one-year price target for Pharvaris N.V. has been revised to $45.73 per share, reflecting a 20.90% increase from the previous estimate of $37.82, with a range from $30.30 to $80.85 per share.
Fund Sentiment: There has been a 29.21% increase in the number of funds reporting positions in Pharvaris, with total shares owned by institutions rising by 28.49% to 58,210K shares, and an average portfolio weight of 1.67%.
Shareholder Activity: General Atlantic increased its holdings in Pharvaris by 6.23% to 8,031K shares, while Foresite Capital Management Iv and venBio Partners also reported increases in their share ownership, with venBio Partners slightly decreasing its portfolio allocation.
Market Outlook: The put/call ratio for Pharvaris is at 0.93, indicating a bullish sentiment among investors, suggesting positive expectations for the stock's performance.
Stocks Rise on Hope for Fed Rate Cuts
Market Performance: The S&P 500, Dow Jones, and Nasdaq 100 all closed higher on Wednesday, with the S&P 500 and Nasdaq reaching three-week highs, supported by a weaker-than-expected ADP employment report that lowered bond yields and increased expectations for a Fed interest rate cut.
Sector Highlights: Chipmakers saw significant gains, with Microchip Technology rising over 12% after a strong earnings forecast, while other tech stocks also performed well. Conversely, concerns over AI demand affected Microsoft, which saw a decline in stock price.
Economic Indicators: The November ADP employment report indicated an unexpected job loss of 32,000, the largest drop in over 2.5 years, while the ISM services index showed unexpected growth, suggesting mixed signals in the labor market and economic activity.
Upcoming Economic Focus: Market attention is on upcoming economic reports, including unemployment claims and personal spending, with a high probability of a 25 basis point rate cut anticipated at the next FOMC meeting on December 9-10.
Stocks Bounce Back Amid Anticipation of Fed Rate Cuts
Market Performance: The S&P 500 is up 0.18%, while the Dow Jones is up 0.47%, and the Nasdaq 100 is down 0.06%. Stock indexes recovered from early losses due to falling bond yields and expectations of a Fed interest rate cut following a weaker-than-expected ADP employment report.
Labor Market Concerns: The November ADP employment report revealed an unexpected job loss of 32,000, the largest decline in over 2.5 years, raising concerns about the labor market's strength and its implications for economic growth.
Corporate Earnings and Economic Indicators: Q3 earnings for S&P 500 companies have exceeded forecasts, with a 14.6% increase, while the ISM services index unexpectedly rose, indicating stronger service-sector activity. Market attention is on upcoming economic reports, including unemployment claims and personal spending.
Stock Movements: Chipmakers like Microchip Technology and Marvell Technology saw significant gains, while stocks like Pure Storage and Gitlab faced declines due to disappointing forecasts. Additionally, cryptocurrency-related stocks rose as Bitcoin reached a two-week high.
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.
Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.
Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.
Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.
